PACB241220C500
- 2.15
- 0.000.00%
Pacific Biosciences of California Newsroom
Pacific Biosciences Price Target Announced at $2.00/Share by UBS
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $6
Pacific Biosciences Is Maintained at Neutral by Piper Sandler
Pacific Biosciences Analyst Ratings
Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2.5
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $4
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
Pacific Biosciences Analyst Ratings
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $7
Pacific Biosciences (PACB) Receives a Buy From Scotiabank
Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2.5
Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
Pacific Biosciences Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pacific Biosciences, Maintains $3.5 Price Target
Piper Sandler Keeps Their Hold Rating on Pacific Biosciences (PACB)